小剂量阿托伐他汀钙片在冠心病心力衰竭患者中的应用效果

Application Effect of Low-dose Atorvastatin Calcium Tablets in Treating Coronary Heart Disease Patients Complicated with Heart Failure

目的分析小剂量阿托伐他汀钙片在冠心病心力衰竭患者中的应用效果。方法选取2014年3月—2017年1月遵化市人民医院收治的冠心病心力衰竭患者106例,采用抽签法分为常规治疗组与小剂量组,每组53例。常规治疗组患者予以常规治疗,小剂量组患者在常规治疗组基础上予以小剂量阿托伐他汀钙片治疗;两组患者均连续治疗12周。比较两组患者治疗前后心功能指标、血流动力学指标、血脂指标、炎性因子,并观察两组患者治疗期间不良反应发生情况。结果治疗前两组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、心排血量(CO)、左心室射血分数(LVEF)比较,差异无统计学意义(P>0.05);治疗后小剂量组患者LVEDD、LVESD短于常规治疗组,CO、LVEF高于常规治疗组(P<0.05)。治疗前两组患者红细胞沉降率(ESR)、血细胞比容(HCT)、纤维蛋白原(FIB)、血浆黏度(PV)比较,差异无统计学意义(P>0.05);治疗后小剂量组患者ESR、HCT、FIB、PV低于常规治疗组(P<0.05)。两组患者治疗前三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及治疗后HDL-C比较,差异无统计学意义(P>0.05);治疗后小剂量组患者TG、TC、LDL-C低于常规治疗组(P<0.05)。治疗前两组患者N末端脑钠肽前体(NT-pro BNP)、超敏C反应蛋白(hs-CRP)、心肌肌钙蛋白I(c Tn I)比较,差异无统计学意义(P>0.05);治疗后小剂量组患者NT-pro BNP、hs-CRP、c Tn I低于常规治疗组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论小剂量阿托伐他汀钙片可有效改善冠心病心力衰竭患者心功能及血流动力学指标,调节血脂代谢,减轻炎性反应,且安全性较高。

Objective To analyze the application effect of low-dose atorvastatin calcium tablets in treating coronary heart disease patients complicated with heart failure.Methods A total of 106 coronary heart disease patients complicated with heart failure were selected in the People's Hospital of Zunhua from March 2014 to January 2017,and they were divided into control group and observation group by the envelope method,each of 53 cases.Patients in control group received conventional treatment,while patients in observation group received low-dose atorvastatin calcium tablets based on conventional treatment;both groups continuously treated for 12 weeks.Index of cardiac function,hemodynamic parameters,blood lipids index,inflammatory cytokines before and after treatment were compared between the two groups,and incidence of adverse reactions was observed during the treatment.Results No statistically significant differences of LVEDD,LVESD,CO or LVEF was found between the two groups before treatment(P>0.05);after treatment,LVEDD and LVESD in observation group were statistically significantly shorter than those in control group,while CO and LVEF in observation group were statistically significantly higher than those in control group(P<0.05).No statistically significant differences of ESR,HCT,FIB or plasma viscosity(PV)was found between the two groups before treatment(P>0.05),while ESR,HCT,FIB and PV in observation group were statistically significantly lower than those in control group after treatment(P<0.05).No statistically significant differences of TG,TC,LDL-C or HDL-C before treatment and HDL-C after treatment was found between the two groups(P>0.05);after treatment,TG,TC and LDL-C in observation group were statistically significantly lower than those in control group(P<0.05).No statistically significant differences of NT-proBNP,hs-CRP or cTnI was found between the two groups before treatment(P>0.05),while NT-proBNP,hs-CRP and cTnI in observation group were statistically significantly lower than those in control group after treatment(P<0.05).No statistically significant differences of incidence of adverse reactions was found between the two groups during the treatment(P>0.05).Conclusion Low-dose atorvastatin calcium tablets can effectively improve the cardiac function and hemodynamic parameters in treating coronary heart disease patients complicated with heart failure,adjust the blood lipid metabolism and relieve the inflammatory reaction,with relatively high safety.